Stoke Therapeutics Appoints Industry Veteran Stephen Tulipano as Chief Financial Officer

BEDFORD, Mass.–(BUSINESS WIRE)–Stoke
Therapeutics, Inc. today announced the appointment of Stephen J.
Tulipano, CPA, MBA as chief financial officer. Mr. Tulipano has more
than 30 years of experience leading the financial operations of private
and public companies in the biotechnology and healthcare industry. In
this new role, Mr. Tulipano will add his deep finance experience to a
management team with a proven track record in developing novel therapies
for patients with rare genetic disorders.

“Steve’s expertise in operating and funding biotechnology companies will
be critical as the Stoke team advances our mission to develop precision
medicines for genetic epilepsies and other diseases,” said Edward M.
Kaye, M.D., chief executive officer of Stoke Therapeutics. “We are
thrilled to have him on our senior leadership team as we continue to
advance our pipeline towards the clinic.”

Prior to joining Stoke, Mr. Tulipano served as chief financial officer
and treasurer of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), where he
worked with the Aldeyra team to advance multiple product candidates in
orphan and non-orphan diseases, led the company’s strategic financings
and completed a development and commercialization agreement with a major
biopharmaceutical company, among other accomplishments. He also spent
five years as chief financial officer of Javelin Pharmaceuticals, Inc.,
a pharmaceutical development company focused on pain relief that was
acquired by Hospira, Inc. in 2010. Prior to that, Mr. Tulipano was
director of corporate accounting at Biogen Inc. (NASDAQ:BIIB), where he
led an accounting team supporting external reporting, research and
development and manufacturing. He holds a B.S. in business
administration and accounting from Salem State College and an MBA from
the Sawyer School of Management at Suffolk University and is a certified
public accountant.

“Stoke’s approach of upregulating protein expression to treat the
underlying cause of disorders like Dravet syndrome is novel and very
exciting,” Tulipano said. “I look forward to joining this team of